Pune, India, March 2020, MRFR Press Release/- Market Research Future has published a Half-Cooked Research Report on the Global AI in Drug Discovery Market.
According to MRFR analysis, the Global AI in Drug Discovery Market is expected to register a CAGR of 40.8% during the forecast period of 2019 to 2025 and is anticipated to reach USD 2,015.1 Million by 2025.
The growth of the global AI in drug discovery market is driven by various factors such as investments by industry giants into the AI business, increasing number of startups operating in AI spectrum for healthcare including drug discovery, machine learning, and other AI technologies and increased use of AI technology by major pharma companies in the drug discovery. In addition, the increasing number of cross-industry partnerships for achieving the common goal of improvement in the drug development outcomes is another factor for the growth of the AI in the drug discovery market. Below is the chart representing the number of AI-driven deals each of the Big Biopharma companies have disclosed till March 2019.
AI-Driven Big Biopharma Deals Disclosed in the Market
Source: MRFR Analysis
However, the high cost of AI integration and lack of adequate infrastructure in low economy countries are thwarting the growth of the AI in the drug discovery market to some extent.
The global AI in the drug discovery market is expected to exhibit great growth potential in the future. Although there are few tech giants at the forefront of the AI technology at the moment, the competitive scenario is changing rapidly as the number of new entrants in the market is increasing continuously. As of February 2020, more than 200 startups have been operating in AI space for the healthcare sector.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/ai-drug-discovery-market-9393
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region is expected to be the largest market owing to the number of big AI platform developers present in the region, such as Microsoft Azure, TensorFlow, and Google AI. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. Increasing demand for AI solutions by the pharmaceutical players such as AbbVie, Genentech, Amgen, and Eli Lilly and Company, among others, is pushing the market growth in the region. The European AI in drug discovery market is the second-largest market, and it has been categorized as Western Europe and Eastern Europe. The Western European market has further been divided as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. High demand for AI platforms and increasing integration into the drug discovery by major players such as Novartis, AstraZeneca, GSK, BI, BMS, and Sanofi, among others, are expected to drive the growth of AI in drug discovery market in the European region.
The AI in drug discovery market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to increasing R&D activities in the region and increasing adoption of the AI technologies by the pharma companies in countries like China and India, the market in Asia-Pacific is expected to grow at a significant rate during the forecast. The AI in drug discovery market in the Middle East & Africa has been divided into the Middle East and Africa.